Valiant Laborato

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0JWS01017
  • NSEID: VALIANTLAB
  • BSEID: 543998
INR
99.20
-2 (-1.98%)
BSENSE

Nov 20

BSE+NSE Vol: 1.06 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 10039033,
    "name": "Valiant Laborato",
    "stock_name": "Valiant Laborato",
    "full_name": "Valiant Laboratories Ltd",
    "name_url": "stocks-analysis/valiant-laborato",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "99.20",
    "chg": -2,
    "chgp": "-1.98%",
    "dir": -1,
    "prev_price": "101.20",
    "mcapval": "550.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543998,
    "symbol": "VALIANTLAB",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0JWS01017",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "1.06 lacs",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/valiant-laborato-10039033-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Valiant Laboratories Ltd Upgraded to Buy on Strong Financial and Valuation Metrics",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/valiant-laboratories-ltd-upgraded-to-buy-on-strong-financial-and-valuation-metrics-4257187",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ValiantLaborato_mojoScore_4257187.png",
        "date": "2026-11-10 08:52:55",
        "description": "Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Hold to Buy as of 9 November 2026. This upgrade follows a comprehensive reassessment of the company’s quality, valuation, financial trend, and technical parameters, reflecting improved fundamentals and an attractive market positioning despite recent price volatility."
      },
      {
        "title": "Valiant Laboratories Falls 9.07%: 4 Key Factors Driving the Weekly Decline",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-falls-907-4-key-factors-driving-the-weekly-decline-4254974",
        "imagepath": "",
        "date": "2026-11-07 11:02:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>Nov 2:</strong> Stock opens at Rs.126.00, down 1.49% amid Sensex gains</p>\n                    <p><strong>Nov 3:</strong> Technical momentum shifts with mixed indicator signals</p>\n                    <p><strong>Nov 4:</strong> Very positive quarterly sales reported but profits contract sharply</p>\n                    <p><strong>Nov 5:</strong> Quality grade upgraded to Hold; valuation shifts to fair</p>\n                    <p><strong>Nov 6:</strong> Week closes at Rs.116.30, down 1.98% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.126.00</d..."
      },
      {
        "title": "Valiant Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-ltd-valuation-shifts-signal-renewed-price-attractiveness-4251390",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ValiantLaborato_valuationdot_4251390.png",
        "date": "2026-11-05 08:03:56",
        "description": "Valiant Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive rating to a fair valuation grade. This change reflects a recalibration of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to its historical averages and peer group, signalling a more attractive price point for investors amid a mixed performance backdrop."
      },
      {
        "title": "Valiant Laboratories Ltd Quality Grade Upgrade Reflects Mixed Business Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-ltd-quality-grade-upgrade-reflects-mixed-business-fundamentals-4251140",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ValiantLaborato_qualitydot_4251140.png",
        "date": "2026-11-05 08:00:41",
        "description": "Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its quality grade upgraded from below average to average, reflecting notable improvements in its business fundamentals. This upgrade, accompanied by a Mojo Score rise to 67.0 and a Hold rating, highlights a shift in key financial metrics such as return on equity (ROE), return on capital employed (ROCE), and debt management, signalling a more stable operational footing despite recent stock price volatility."
      },
      {
        "title": "Valiant Laboratories Ltd Reports Very Positive Quarterly Financial Performance Amid Mixed Market Returns",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-ltd-reports-very-positive-quarterly-financial-performance-amid-mixed-market-returns-4250744",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/11/ValiantLaborato_fintrenddot_4250744.png",
        "date": "2026-11-04 11:00:37",
        "description": "Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has reported a mixed set of quarterly results for September 2026, reflecting a significant shift in its financial trend from positive to very positive. Despite record quarterly net sales and improved return on capital employed, the company’s profitability metrics have shown notable contraction, prompting a downgrade in its Mojo Grade from Hold to Sell as of 19 August 2026."
      },
      {
        "title": "Valiant Laboratories Ltd Shows Bullish Momentum Amid Technical Upgrades",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-ltd-shows-bullish-momentum-amid-technical-upgrades-4242834",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ValiantLaborato_technicaldot_4242834.png",
        "date": "2026-10-29 08:03:10",
        "description": "Valiant Laboratories Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by a combination of technical indicators and a robust year-to-date return of 81.16%, significantly outperforming the Sensex’s negative 14.05% over the same period. Investors and analysts are closely monitoring these developments as the stock trades near its 52-week high, signalling renewed optimism in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Valiant Laboratories Ltd Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-ltd-technical-momentum-shifts-amid-mixed-indicator-signals-4241540",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ValiantLaborato_technicaldot_4241540.png",
        "date": "2026-10-28 08:05:48",
        "description": "Valiant Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a recent day decline of 1.97%, the stock’s year-to-date return remains robust at 77.66%, significantly outperforming the Sensex’s negative 13.64% over the same period. This article analyses the latest technical indicators, including MACD, RSI, moving averages, and other momentum oscillators, to provide a comprehensive view of the stock’s current market positioning and outlook."
      },
      {
        "title": "Valiant Laboratories Ltd Technical Momentum Shifts Signal Bullish Outlook Amid Mixed Indicators",
        "link": "https://researchintel.adityabirlamoney.com/news/stocks-in-action/valiant-laboratories-ltd-technical-momentum-shifts-signal-bullish-outlook-amid-mixed-indicators-4238361",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ValiantLaborato_technicaldot_4238361.png",
        "date": "2026-10-26 08:03:02",
        "description": "Valiant Laboratories Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish trend, supported by mixed but increasingly positive signals from key indicators such as MACD, RSI, and moving averages. Despite a modest day decline of 1.97%, the stock’s year-to-date return of 84.88% significantly outpaces the Sensex’s negative 14.19%, highlighting strong underlying strength in this pharmaceuticals and biotechnology micro-cap."
      },
      {
        "title": "Valiant Laboratories Ltd is Rated Hold",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/valiant-laboratories-ltd-is-rated-hold-4237904",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ValiantLaborato_mojoScore_4237904.png",
        "date": "2026-10-25 10:10:03",
        "description": "Valiant Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 August 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 25 October 2026, providing investors with an up-to-date view of the company's fundamentals, valuation, financial trends, and technical outlook."
      }
    ],
    "total": 116,
    "sid": "10039033",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/valiant-laboratories-10039033"
  },
  "announcements": [
    {
      "caption": "Intimation Of Sad Demise Of The Member Of A Promoter Group Of The Company",
      "datetime": "15-Nov-2026",
      "details": "Intimation of sad demise of the member of a Promoter Group of the Company",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "04-Nov-2026",
      "details": "Copy of Newspaper Publication of Financial Results for quarter and half year ended September 30 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Half Year Ended September 30 2026.",
      "datetime": "02-Nov-2026",
      "details": "Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Valiant Laboratories Ltd has announced <strong>1:4</strong> rights issue, ex-date: 18 Jul 25",
          "dt": "2025-07-18",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Intimation Of Sad Demise Of The Member Of A Promoter Group Of The Company

15-Nov-2026 | Source : BSE

Intimation of sad demise of the member of a Promoter Group of the Company

Announcement under Regulation 30 (LODR)-Newspaper Publication

04-Nov-2026 | Source : BSE

Copy of Newspaper Publication of Financial Results for quarter and half year ended September 30 2026.

Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Half Year Ended September 30 2026.

02-Nov-2026 | Source : BSE

Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30 2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

Valiant Laboratories Ltd has announced 1:4 rights issue, ex-date: 18 Jul 25